Poor anti-VEGF responses linked to genetic variation in immune regulation

December 5, 2016

Anti-VEGF therapies are commonly used to stabilize deteriorating vision in patients with wet age-related macular degeneration (wet AMD). Vascular endothelial growth factor, or VEGF, is a signaling molecule that helps maintain blood vessels in the eye and other organs, but its overabundance in wet AMD patients can lead to overgrowth of vessels that causes vision loss. Though reducing VEGF signaling with anti-VEGF therapies has positive effects in many patients, some individuals continue to experience vision deterioration during treatment.

In a study published this week in the JCI, Martin Friedlander's lab at Scripps Research Institute investigated whether in an immune system component called the complement system may contribute to during anti-VEGF therapy in some wet-AMD patients.

Prior work suggested that patients who do not respond well to anti-VEGF therapy often expressed variations in the genes encoding complement system proteins, but it was not known whether these variations interacted with VEGF signaling during treatment.

In the current study, researchers examined the these genetic variations in human retinal cells and observed that they led to complement system dysregulation. Blocking VEGF signaling enhanced this dysregulation, providing evidence for a link between VEGF signaling and complement system activation.

These findings suggest that screening wet AMD patients for genetic variations in the complement system may help identify individuals at risk for adverse responses to anti-VEGF therapy.

Explore further: A culprit behind brain tumor resistance to therapy

More information: Lindsay S. Keir et al, VEGF regulates local inhibitory complement proteins in the eye and kidney, Journal of Clinical Investigation (2016). DOI: 10.1172/JCI86418

Related Stories

A culprit behind brain tumor resistance to therapy

March 5, 2012
Persistent protein expression may explain why tumors return after therapy in glioblastoma patients, according to a study published on March 5th in the Journal of Experimental Medicine.

Topical dorzolamide-timolol beneficial in neovascular AMD

February 26, 2016
(HealthDay)—Topical dorzolamide hydrochloride-timolol appears to reduce central subfield thickness and subretinal fluid in eyes of patients with neovascular age-related macular degeneration (AMD) and incomplete response ...

High VEGF signaling score tied to lung cancer prognosis

February 22, 2012
(HealthDay) -- A high vascular endothelial growth factor (VEGF) signaling score correlates with good prognosis in patients with early squamous cell carcinoma (SCC) of the lung, according to a study published online Feb. 21 ...

Treating eye diseases with anti-VEGF therapies may have side effects

January 11, 2013
A new Investigative Ophthalmology & Visual Science (IOVS) article reveals that increasingly aggressive therapies that block VEGF could cause damage in treating eye diseases. Scientists discovered inhibiting anti-VEGF might ...

Better treatment for brain cancer revealed by new molecular insights

July 9, 2012
Nearly a third of adults with the most common type of brain cancer develop recurrent, invasive tumors after being treated with a drug called bevacizumab. The molecular underpinnings behind these detrimental effects have now ...

Targeting two angiogenesis pathways could improve results of glioblastoma treatment

April 4, 2016
Two companion papers from Massachusetts General Hospital (MGH) research teams suggest that targeting multiple angiogenesis pathways simultaneously could help overcome the resistance to anti-angiogenic treatment inevitably ...

Recommended for you

World's blind population to soar: study

August 3, 2017
The world's blind will increase threefold from about 36 million today to 115 million in 2050 as populations expand and individuals grow ever older, researchers said Thursday.

Simulations signal early success for fractal-based retinal implants

July 27, 2017
Computer simulations of electrical charges sent to retinal implants based on fractal geometry have University of Oregon researchers moving forward with their eyes focused on biological testing.

Scientists regenerate retinal cells in mice

July 26, 2017
Scientists have successfully regenerated cells in the retina of adult mice at the University of Washington School of Medicine in Seattle.

Genome editing with CRISPR-Cas9 prevents angiogenesis of the retina

July 24, 2017
A research team from the Schepens Eye Research Institute of Massachusetts Eye and Ear has successfully prevented mice from developing angiogenesis of the retina—the sensory tissue at the back of the eye—using gene-editing ...

Too little vitamin D may hinder recovery of injured corneas

July 24, 2017
Injury or disease in combination with too little vitamin D can be bad for the window to your eyes.

Combination of type 2 diabetes and sleep apnoea indicates eyesight loss within four years

July 4, 2017
Research led by the University of Birmingham has discovered that patients who suffer from both Type 2 diabetes and obstructive sleep apnoea are at greater risk of developing a condition that leads to blindness within an average ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.